About the conference

The two-day conference was entirely dedicated to bringing together the latest advances, challenges and opportunities for developing medicinal products and medicinal devices for paediatric use.

This year we introduce preconference workshops focussing on ‘Neonatal and Paediatric Pharmacology’ and ‘Paediatric Regulatory Framework’. These preconference workshops are designed to maximise your learning experience by a specialist in the topic area.

Moving on to the plenary sessions with the focus on Paediatric Biopharmaceutics provided the latest trends, learn how Japanese children take their medicines in relation to cultural differences and the way in which Pharma has responded, a session on patient public engagement and ‘case studies/PIPs lessons learned’. An Innovation Show Case gave an opportunity for companies to present less traditional yet relevant technologies for children medicines.

The EuPFI thematic sessions covering the five work streams of EuPFI (taste masking and testing, excipients, age appropriateness of formulations, extemporaneous formulations and administration devices) provided an overview of the current practices and challenges in the aforementioned areas, to illustrate specific remedies utilized by paediatric drug development teams to overcome hurdles. The vibrant poster session with many selected by peer review for oral presentation.

The conference enabled participants to present, discuss breakthroughs and expand their knowledge on recent developments and challenges in the area of paediatric medicines and administration devices, from academia, industry, hospitals, and regulatory authorities. It brought together international leaders in the fields of paediatric formulation development to discuss emerging topics in these areas.

We invite you to note the dates of 6^th EuPFI conference in your diary and begin planning your participation, as well as your abstract submissions.

Conference Proceedings

EuPFI 2013 Abstracts

EuPFI 2013 Highlights

IJP Special Issue EuPFI 2013

Programme

EuPFI 2013 updated programme, including the Soap Box Sessions is available here

The detail schedule will be announced shortly. Sign up to our mailing list here and we will send you an email when the programme is online and keep visiting the website for conference updates in the meanwhile.

Find out what is new for EuPFI 2013 below,

Pre-Conference Workshops

In 2013, EuPFI will begin pre-conference workshops dedicated to specific topics. Two workshops: Neonatal and Paediatric Pharmacology & Paediatric Regulatory Framework have been organised. Each workshop will be of one and half hours. It has been carefully scheduled to allow the participants to attend either of them or both the workshops as per their needs. These workshops will be led by 1-2 experts and provide in depth training in the topics. This focused approach will enable attendees to significantly improve their knowledge and comfort with handling a particular problem they deal with in paediatric drug development. The sessions will combine information and interactive discussion. On the completion of the course, attendees will be issued a certificate of attendance.

Plenary Lectures

Key topics will meticulously addressed in all its facets. 6 eminent experts deliver a 30-minute presentation on different aspects of the paediatric formulation development and then discuss it extensively with the audience over the course of 60 minutes.

Four Focus Sessions

The agenda includes four thematic focus sessions, each of which will address an important challenges in developing paediatric medicines. Each session will have two range of topics that will presented and discussed in to maximize value and learning. The sessions themselves will always balance context vs. detail, i.e. recent important scientific developments vs. daily clinical practice. Together, the sessions will effectively provide an overview of the current practices and challenges in the aforementioned areas, to illustrate specific remedies utilized by paediatric drug development teams to overcome hurdles

Innovative show case

An exciting opportunity to present the next big idea to the international leaders in paediatric drug development. 4 companies will present less traditional yet relevant technologies for children medicines.

ABSTRACT SUBMISSION IS NOW CLOSED. THANK YOU VERY MUCH FOR YOUR CONTRIBUTION

Instructions for Poster and Oral Presenters

Oral Presentation

Oral presentations (except plenary and keynote) have a 12 minutes slot – please prepare a PowerPoint presentation that lasts for up to 10 minutes MAXIMUM to allow 2 minutes for discussion after your talk. This equates to roughly 10 slides including your title and acknowledgement slides.  Please make sure you finish your talk with in 10 minutes - it is a good idea to rehearse it beforehand to check your timings- to allow plenty of time for discussion from the audience. We will give you a warning at 9 minutes so you have a minute to wrap up. We will be very strict about timing and will stop you when your 10 minutes is up even if you have not finished. If you need any further information please do not hesitate to get in touch. Power Point presentation of all speakers must be delivered to the registration desk on the first day of the conference and sent to admin@eupfi.org by close of play 5th September 2013. Conference organisers will be available to help you download and run-through. Final program with the time and date of presentations will be posted on the congress web site by September 10th.

The 10 best abstracts will be presented as oral presentations during the conference (all other abstracts will be presented as posters).

Poster Presentation - click here

ABSTRACT WITHDRAWAL

If you wish to withdraw an abstract, please contact the Conference Organisers before May 30^th, 2013, otherwise the papers will be posted on the Conference website.

Please contact the Conference Organisers at admin@eupfi.org for any enquiries related to abstract submissions.

Abstract submissions deadline: May 30^th, 2013

Registration Guidelines

All participants are kindly recommended to register via Online Registration Form on APV website. Please fax this document to APV Headquarters: 0049 6131 9769-69 or send it via email to apv@apv-mainz.de. Please read the instructions on the APV website carefully.

To benefit from the reduced early registration fee, please process your registration before July 15^th, 2013.

Upon submitting the Registration Form, You will receive a confirmation by e-mail of your registration with the invoice.

All participants are kindly requested to register in advance by completing and submitting the Registration Form with the appropriate fees.

Registration fees

Please note unpaid pre-registration will not be considered as a valid registration unless fully paid and confirmed. Pre-registration summary therefore cannot be taken as a valid registration confirmation. Please make sure to pay your registration fee within the time frame for early or regular registration.

Students have to submit a copy of their student ID to the Conference email/contact address or fax number. Please note that if we do not receive this certification within 7 days after your data submission your registration will not be considered as valid.

*Early Bird Deadline is 15th July 2013

Delegate registration fee includes

Admission to scientific sessions, exhibition and poster area
Conference materials
Coffee breaks
Lunches
Conference Dinner & Social Programme

Insurance

The registration fees do not include insurance of participants against accidents, sickness, cancellation, theft, property damage or loss. Participants are advised to take out adequate personal insurance.

Confirmation

Upon receipt of the correct registration fee (clear of bank charges), each participant will receive a confirmation of registration. Please bring this confirmation to the Registration desk at the conference venue as proof of your registration. Confirmation will be sent upon receipt of payment.

Payment

All fees for the Conference registration should be paid in EUR (€), free of all bank charges.

Payment options

credit card payment (Visa, Eurocard/Mastercard)
by bank transfer

Cancellation / Refund Policy

We would like to point out that participation can be cancelled free of charge within two weeks of registration via the web.

Publication in the list of participants

In case you wish not to include your name and email address in the list of participants please send email to the Conference secretariat.

Responsibility

The participant acknowledges that he/she has no right to lodge damage claims against the organisers should the holding of the Conference be hindered or prevented by unexpected political or economic events or generally by force majeure, or should the non-appearance of speakers or other reasons necessitate programme changes. With registration, the participant accepts this proviso.

Accomodation Information

Official Conference Hotel

The official conference hotel for EuPFI Barcelona 2013 is the "HOTEL SANTOS PORTA FIRA ****"

Conference guests can make their booking at this hotel using the online booking form available here

Deadline for special conference rate: 10th August, 2013. Special rate: Single room incl. EUR 100,00 VAT per night (breakfast buffet not included)

Other Hotels

For other hotels near to conference venue click here

Workshops Presentation

Workshop 1: Neonat/Peads pharmacology

Opening Presentation
Adolf Valls-i-Soler, University of the Basque Country, Cruces University Hospital, Bilbao, Bizkaia, Spain

From birth to adulthood, pharmacokinetics and pharmacodynamics
Dr. Monica Rodriguez Dr. Valvanera Vozmediano

Considerations about paediatric dosing

Dra. M. Pozas. Sº Farmacia

An example with fentanyl
Dr. Monica Rodriguez Dr. Valvanera Vozmediano

Workshop 2: Introduction to Paediatric regulatory framework

Dirk Mentzer, PDCO Vice-Chair, Paul-Ehrlich-Institut, Langen, Germany

Plenary Presentation

Global Research in Paediatrics (GRiP) – Network of Excellence

Kalle Hoppu, Helsinki University, Helsinki, Finland

Paediatric Biopharmaceutics: Current status and future decisions

Hannah Batchelor, MCRN University of Birmingham, Birmingham, United Kingdom

Patient involvement in paediatric medicine development and improving formulations

Cor Oosterwijk, Patients Network for Medical Research and Health EGAN, Soest, The Netherlands

How do Japanese children take their medicines?

Hidefumi Nakamura, National Center for Child Health and Development, Tokyo, Japan

The place of dosage form innovation and the OTC market: the price to pay

Paul Goggin, Pfizer Consumer Healthcare, Maidenhead, United Kingdom

Regulatory perspectives on acceptability testing of dosage form in children

Piotr Kozarewicz, European Medicine Agency, London, United Kingdom

Focus Session Presentations

Focus session on Age Appropriateness of Formulations

Patient-centred administration friendly dosage forms
Simon Bryson, Proveca Ltd, Cheshire, United Kingdom

Focus session on Modification of Dosage Forms Required for Children

Pediatric “ad hoc” preparations of TamifluTM

Carsten Timpe, F. Hoffmann-La Roche AG, Basel, Switzerland

Focus Session on Devices

A respiratory product for young children – development and submission experiences
Stefan Leiner, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Focus session on Taste Masking and Taste Testing

Interlaboratory testing of e-tongues
Miriam Pein, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Case Studies Presentations

PIP statistics and industry case studies

Gesine Winzenburg, Novartis, Basel, Switzerland

Learnings of Recent PIPs

Albertina Arien, Janssen Research and Development, Belgium

Innovation Showcase Presentations

Patient centric medication – Elegant dose forms for developing better treatments

Leon Grother, Catalent Pharma Solutions, Swindon, United Kingdom

Taste masking using an aqueous ethylcellulose film coating

Kevin Huges, Colorcon, Dartfort, United Kingdom

Innovative micropellets for paediatric drug products

Annette Grave, Glatt GmbH, Binzen, Germany

Combining taste masking and convenient application - Innovative formulation concepts for children

Sandra Klein, Losan Pharma GmbH, Neuenburg, Germany

Orodispersible Films, a new treatment option especially suited for children

Armin Breitenbach, Tesa Labtec GmbH, Langenfeld, Germany

Administration Devices

#8 Medication Errors In Neonatal Units And Strategies To Avoid Them: A Review Of The Literature.

Elena Santesteban, Ainara Campino, and Adolfo Valls I Soler

#22 Immediate-Release Carbamazepine Formulation For Individually Dosing By The Solid Dosage Pen

Eva Julia Laukamp, Markus Thommes, and Joerg Breitkreutz

#25 Age-Specific In Vitro Investigations Using A Single Dose Dry Powder Inhaler

Sandra Lindert

#43 Predictability Of The Extrathoracic And Pulmonary Deposition Using An Idealized Pediatric Mouth-Throat Model

Antje Below, Deborah Bickmann, and Joerg Breitkreutz

#49 Performance Study Of A Nasal Product

Deborah Bickmann

Developing Age Appropriate Formulations/ Compliance-Adherence Issues

# 2 Influence Of Thickening Agents On The Properties Of Orodispersible Drug-Free Polymer Films

Christina Woertz and Peter Kleinebudde

#10 How To Determine Suitable Mechanical Strength Of Orodispersible Fiilms?

Maren Preis and Jörg Breitkreutz

#14 In Vitro In Vivo Correlation (Ivivc) For Paracetmol And Caffeine In Timpediatric Simulating Gi Conditions Of (Pre-Term) Neonates, Infants And Toddlers

Bart Anneveld, Jeroen Bongers, Saskia N. de Wildt, Barbara A. de Koning, Mark L. Huijsman, Miriam G. Mooij, Sieto Bosgra, Lidwien M. Hanff, Wouter Vaes, and Rob Havenaar

#15 Prospective Work On Developing Paediatric Drug Formulations For Neuropediatric Department In A French University Hospital

AgatheRoger, Damien Lannoy, Elodie Simon, Hélène Beaussart, Christophe Berneron, Louis Vallée, and Pascal Odou

#19 Development Of A Paediatric Oral Solution Of Bilastine

E. Beascoa, I. Artaiz, E. Corta, I. Justo, C. Pumar, L. González, L. Díez, I. Bueno, And A. Gonzalo

#21 Pediatric Oral Formulations For Valsartan And Candesartan

Malgorzata Sznitowska, Katarzyna Centkowska, Katarzyna Hoppe, Anna Kluk, Eliza Wolska, and Monika Musko

#26 Development Of Fast Dispersible Tablets Of Cobicistat

Joanna Koziara and Lei Hong

#29 Three Possibilities For Solubilizing Lorazepam In A Pediatric Oral Liquid Formulation

Iris van der Velde, Lidwien Hanff, Andras Vermes, Birgit Koch, Oscar Smeets, Doerine Postma, and Arnold Vulto

#30 Development Of A Pediatric Amlodipine Solution For Oral Use

Iris van der Velde, Lidwien Hanff, Andras Vermes, Birgit Koch, Oscar Smeets, Doerine Postma, and Arnold Vulto

#32 Development Of Buccal Films As Novel Dosage Form For Paediatric Use

Ramona Trastullo, Valentina Ragazzini, Angela Abruzzo, Barbara Luppi, Teresa Cerchiara, and Federica Bigucci

#33 Pharmaceutical Industry Approaches To the Formulation Development Of Paediatric Products

Jennifer Walsh and Kevin Hughes

#34 Tablet Size Acceptability In Paediatric Populations: Preliminary Data

Hannah K. Batchelor, Rebecca Venables, John Marriott, Kevin Hughes, Charlotte Miller, Heather Stirling, and Claire Callens

#36 Preferences For Tablet Shape And Colour In Paediatric Populations: Preliminary Data

Hannah Batchelor, Rebecca Venables, John Marriott, Kevin Hughes, Charlotte Miller, Heather Stirling, and Claire Callens

#37 Measuring The Volume Of Liquid That Paediatric Patients Use To Take Tablets

Hannah Batchelor and John Marriott

#44 Tacrolimus Oral Suspensions Prepared From Capsules With Distinct Excipients - Stability And Optimization

Joana Gomes, Paulo Lobão, and Maria Fernanda Bahia

#45 Development Of Modified Release Paediatric Liquids

Kofi Asare-Addo, Mohammed Mahdi, and Alan Mark Smith

#46 Potential Reasons For The Variability Of Oral Ibuprofen Pharmacokinetics In Neonates - An In Vitro Study

Elisabeth Kersten and Sandra Klein

#47 Paediatric Milk-Based Dispersible Tablets: A Design Of Experiment Approach

Samuel Ebiowe Fanifini Orubu, Nicholas John Hobson, Anne Cram, Kate Boxell, and Catherine Tuleu

#50 Liquids Or Tablets For Children:Making The Choice

Rebecca Venables1 V, James Hodson H, Hannah B, Heather S, and John M

#51 Predicting Nasal Discomfort With The Slug Mucosal Irritation Test

Joke Lenoir, Ilse Claerhout, Philippe Kestelyn, Jean-Paul Remon, and Els Adriaens

#59 End-user Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 1: School Children and Adolescents

Sejal Ranmal, Celine Bilbul, Anne Cram, Catherine Tuleu

#60 End-user Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 2: Parents and Carers

Sejal Ranmal, Celine Bilbul, Anne Cram, Catherine Tuleu

Modification of Dosage Forms ForChildren

#6 Multiparticulate Dosage Form With Fast Disintegration for Pediatric Use – Development And Characterization

ThanhHuong Hoang Thi and Marie-Pierre Flament

#16 The Effect Of Food And Co-Administration On Amoxicillin Bioaccessiblity As Studied In The In Vitro Model Timpediatric

Bart Anneveld, Jeroen Bongers, Saskia N. de Wildt, Barbara A. de Koning, Miriam G. Mooij, Mark L. Huijsman, Lidwien Hanff, Wouter Vaes, and Robert Havenaar

#17 Problems With The Administration of Oral Formulations To Children: #Perspectives Of Medical Practitioners, Pharmacists And Nurses.

Rebecca Hayley Venables, Heather Stirling, and John Marriott

#18 Oral Formulation-Related Barriers to Medicines Administration In Children With Chronic Conditions: Views Of Parents And Young People

Rebecca Hayley Venables, Heather Stirling, and John Marriott

#39 Importance of Polymorphism In Paediatric Oral Liquid Pharmaceutical Compounding Of Hydrocortisone

Nora Provenza, Beatriz Clares, Mireia Mallandrich, Maria Adolfina Ruiz, and Ana Cristina Calpena

#41 Development of An Extemporaneous Hydroxyurea syrup For Paediatric Use

Stuart T. Charlton, Tila Balasuriya, Elisabeth Corbett, Chris Knutsen, Sharon Lamb, and Stephen Grier